Literature DB >> 20665806

Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD.

Stephen B Mason1, Yun Liang, Rachel M Sinders, Caroline A Miller, Tracy Eggleston-Gulyas, Robin Crisler-Roberts, Peter C Harris, Vincent H Gattone.   

Abstract

The rat Pck gene is orthologous to the human PKHD1 gene responsible for autosomal recessive polycystic kidney disease (ARPKD). Both renal and hepatic fibrocystic pathology occur in ARPKD. Affected humans have a variable rate of progression, from morbidly affected infants to those surviving into adulthood. This study evaluated the PCK rat, a model of slowly progressive ARPKD. This model originated in Japan and was rederived to be offered commercially by Charles River Laboratories (Wilmington, MA). Previous studies have described the basic aspects of PCK pathology from privately held colonies. This study provides a comprehensive characterization of rats from those commercially available. Rats were bred, maintained on a 12:12 hr light/dark cycle, fed (7002 Teklad), and water provided ad libitum. Male and female rats were evaluated from 4 through 35 weeks of age with histology and serum chemistry. As the hepatorenal fibrocystic disease progressed beyond 18 weeks, the renal pathology (kidney weight, total cyst volume) and renal dysfunction (BUN and serum creatinine) tended to be more severe in males, whereas liver pathology (liver weight as % of body weight and hepatic fibrocystic volume) tended to be more severe in females. Hyperlipidemia was evident in both genders after 18 weeks. Bile secretion was increased in PCK rats compared with age-matched Sprague Dawley rats. The PCK is an increasingly used orthologous rodent model of human ARPKD. This characterization study of hepatorenal fibrocystic pathology in PCK rats should help researchers select stages of pathology to study and/or monitor disease progression during their longitudinal studies. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 20665806      PMCID: PMC3081615          DOI: 10.1002/ar.21166

Source DB:  PubMed          Journal:  Anat Rec (Hoboken)        ISSN: 1932-8486            Impact factor:   2.064


  29 in total

Review 1.  Stereologic methods and their application in kidney research.

Authors:  J R Nyengaard
Journal:  J Am Soc Nephrol       Date:  1999-05       Impact factor: 10.121

2.  Characterization of a novel polycystic kidney rat model with accompanying polycystic liver.

Authors:  M Katsuyama; T Masuyama; I Komura; T Hibino; H Takahashi
Journal:  Exp Anim       Date:  2000-01

3.  Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease.

Authors:  Tatyana V Masyuk; Bing Q Huang; Anatoliy I Masyuk; Erik L Ritman; Vicente E Torres; Xiaofang Wang; Peter C Harris; Nicholas F Larusso
Journal:  Am J Pathol       Date:  2004-11       Impact factor: 4.307

4.  Epidermal growth factor receptor tyrosine kinase inhibition is not protective in PCK rats.

Authors:  Vicente E Torres; William E Sweeney; Xiaofang Wang; Qi Qian; Peter C Harris; Philip Frost; Ellis D Avner
Journal:  Kidney Int       Date:  2004-11       Impact factor: 10.612

5.  Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat.

Authors:  Tatyana V Masyuk; Bing Q Huang; Christopher J Ward; Anatoliy I Masyuk; David Yuan; Patrick L Splinter; Rachaneekorn Punyashthiti; Eric L Ritman; Vicente E Torres; Peter C Harris; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

6.  The autosomal recessive polycystic kidney disease protein is localized to primary cilia, with concentration in the basal body area.

Authors:  Shixuan Wang; Ying Luo; Patricia D Wilson; George B Witman; Jing Zhou
Journal:  J Am Soc Nephrol       Date:  2004-03       Impact factor: 10.121

7.  Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist.

Authors:  Vincent H Gattone; Xiaofang Wang; Peter C Harris; Vicente E Torres
Journal:  Nat Med       Date:  2003-09-21       Impact factor: 53.440

8.  Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.

Authors:  Christopher J Ward; David Yuan; Tatyana V Masyuk; Xiaofang Wang; Rachaneekorn Punyashthiti; Shelly Whelan; Robert Bacallao; Roser Torra; Nicholas F LaRusso; Vicente E Torres; Peter C Harris
Journal:  Hum Mol Genet       Date:  2003-08-12       Impact factor: 6.150

9.  EGF receptor tyrosine kinase inhibition attenuates the development of PKD in Han:SPRD rats.

Authors:  Vicente E Torres; William E Sweeney; Xiaofang Wang; Qi Qian; Peter C Harris; Philip Frost; Ellis D Avner
Journal:  Kidney Int       Date:  2003-11       Impact factor: 10.612

10.  PKHD1 protein encoded by the gene for autosomal recessive polycystic kidney disease associates with basal bodies and primary cilia in renal epithelial cells.

Authors:  Ming-Zhi Zhang; Weiyi Mai; Cunxi Li; Sae-youll Cho; Chuanming Hao; Gilbert Moeckel; Runxiang Zhao; Ingyu Kim; Jikui Wang; Huaqi Xiong; Hong Wang; Yasunori Sato; Yizhong Wu; Yasuni Nakanuma; Marusia Lilova; York Pei; Raymond C Harris; Song Li; Robert J Coffey; Le Sun; Dianqing Wu; Xing-Zhen Chen; Matthew D Breyer; Zhizhuang Joe Zhao; James A McKanna; Guanqing Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  19 in total

1.  Inhibition of cyst growth in PCK and Wpk rat models of polycystic kidney disease with low doses of peroxisome proliferator-activated receptor γ agonists.

Authors:  Stephanie M Flaig; Vincent H Gattone; Bonnie L Blazer-Yost
Journal:  J Transl Int Med       Date:  2016-09-23

2.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

Review 3.  Animal models of biliary injury and altered bile acid metabolism.

Authors:  Valeria Mariotti; Mario Strazzabosco; Luca Fabris; Diego F Calvisi
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2017-07-11       Impact factor: 5.187

4.  Quantitative magnetic resonance imaging assessments of autosomal recessive polycystic kidney disease progression and response to therapy in an animal model.

Authors:  Bernadette O Erokwu; Christian E Anderson; Chris A Flask; Katherine M Dell
Journal:  Pediatr Res       Date:  2018-05-02       Impact factor: 3.756

5.  Altered Expression and Function of Hepatic Transporters in a Rodent Model of Polycystic Kidney Disease.

Authors:  Jacqueline Bezençon; James J Beaudoin; Katsuaki Ito; Dong Fu; Sharin E Roth; William J Brock; Kim L R Brouwer
Journal:  Drug Metab Dispos       Date:  2019-06-03       Impact factor: 3.922

6.  MALDI imaging MS reveals candidate lipid markers of polycystic kidney disease.

Authors:  Hermelindis Ruh; Theresia Salonikios; Jens Fuchser; Matthias Schwartz; Carsten Sticht; Christina Hochheim; Bernhard Wirnitzer; Norbert Gretz; Carsten Hopf
Journal:  J Lipid Res       Date:  2013-07-12       Impact factor: 5.922

7.  Deletion of airway cilia results in noninflammatory bronchiectasis and hyperreactive airways.

Authors:  Sandra K Gilley; Antine E Stenbit; Raymond C Pasek; Kelli M Sas; Stacy L Steele; May Amria; Marlene A Bunni; Kimberly P Estell; Lisa M Schwiebert; Patrick Flume; Monika Gooz; Courtney J Haycraft; Bradley K Yoder; Caroline Miller; Jacqueline A Pavlik; Grant A Turner; Joseph H Sisson; P Darwin Bell
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-11-08       Impact factor: 5.464

8.  Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.

Authors:  Bonnie L Blazer-Yost; Julie Haydon; Tracy Eggleston-Gulyas; Jey-Hsin Chen; Xiaofang Wang; Vincent Gattone; Vicente E Torres
Journal:  PPAR Res       Date:  2010-11-01       Impact factor: 4.964

9.  Bile Acids as Potential Biomarkers to Assess Liver Impairment in Polycystic Kidney Disease.

Authors:  William J Brock; James J Beaudoin; Jason R Slizgi; Mingming Su; Wei Jia; Sharin E Roth; Kim L R Brouwer
Journal:  Int J Toxicol       Date:  2018 Mar/Apr       Impact factor: 2.032

10.  Proteostasis disturbances and endoplasmic reticulum stress contribute to polycystic liver disease: New therapeutic targets.

Authors:  Alvaro Santos-Laso; Laura Izquierdo-Sanchez; Pedro M Rodrigues; Bing Q Huang; Mikel Azkargorta; Ainhoa Lapitz; Patricia Munoz-Garrido; Ander Arbelaiz; Francisco J Caballero-Camino; Maite G Fernández-Barrena; Raul Jimenez-Agüero; Josepmaria Argemi; Tomas Aragon; Felix Elortza; Marco Marzioni; Joost P H Drenth; Nicholas F LaRusso; Luis Bujanda; Maria J Perugorria; Jesus M Banales
Journal:  Liver Int       Date:  2020-05-06       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.